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A B S T R A C T
Parkinson's disease (PD) is a multifactorial disorder with complex etiology. The most prevalent PD associated
mutation, LRRK2-G2019S is linked to familial and sporadic cases. Based on the multitude of genetic predis-
positions in PD and the incomplete penetrance of LRRK2-G2019S, we hypothesize that modifiers in the patients'
genetic background act as susceptibility factors for developing PD. To assess LRRK2-G2019S modifiers, we used
human induced pluripotent stem cell-derived neuroepithelial stem cells (NESCs). Isogenic controls distinguish
between LRRK2-G2019S dependent and independent cellular phenotypes. LRRK2-G2019S patient and healthy
mutagenized lines showed altered NESC self-renewal and viability, as well as impaired serine metabolism. In
patient cells, phenotypes were only partly LRRK2-G2019S dependent, suggesting a significant contribution of the
genetic background. In this context we identified the gene serine racemase (SRR) as a novel patient-specific,
developmental, genetic modifier contributing to the aberrant phenotypes. Its enzymatic product, D-serine, res-
cued altered cellular phenotypes. Susceptibility factors in the genetic background, such as SRR, could be new
targets for early PD diagnosis and treatment.
1. Introduction
Parkinson's disease (PD) is the second most common progressive
neurodegenerative disease. Pathophysiologically, PD is characterized
by the loss of midbrain dopaminergic neurons (DN) in the substantia
nigra. The triggers that lead to the onset of PD and finally to DN de-
generation are poorly understood and thus, PD pathogenesis remains
largely elusive with no effective protective treatment. PD has been
proposed to encompass different multifactorial diseases, with similar
phenotypic outcome [1]. Multiple genetic predispositions, monogenetic
mutations, and risk loci can cause similar parkinsonian phenotypes and
symptoms.
The most common mutation that causes autosomal dominant PD is a
glycine to serine substitution at position 2019 (G2019S) in the leucine-
rich-repeat-kinase-2 (LRRK2) [2,3]. LRRK2 is of special interest as its
mutations are the monogenetic cause of familial PD and the reason for
1–2% of the sporadic cases [4,5]. Furthermore, a single nucleotide
polymorphism (SNP) in the LRRK2 gene acts as common risk modifier
for developing PD [6]. Epidemiologic studies suggest that the age of
onset between individuals carrying LRRK2-G2019S is highly variable
and that different ethnicities show higher prevalence's [7]. Accordingly
genetic variations within the patient-specific genetic background may
underlie this variability. Such so-called second hits may explain why
asymptomatic carriers exist, why the penetrance of LRRK2-G2019S is
age-dependent and why the LRRK2 phenotypic spectrum is practically
indistinguishable from that of idiopathic PD (iPD) [4].
Previous studies suggest that LRRK2 has an impact on neural stem
cell (NSC) proliferation and integrity and plays a role in neurogenesis
[8–12]. Furthermore, LRRK2 expression is enhanced in the stem cell
niches of the developing mouse brain during neurogenesis [13]. These
observations imply a possible link between LRRK2, impaired neuro-
genesis, and the onset or progression of PD and therefore, we
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hypothezise that PD might have a neuro-developmental component that
could explain DN vulnerability.
To explore this hypothesis, we investigated human PD patient-spe-
cific, iPSC-derived, neuroepithelial stem cells (NESC). To differentiate
between LRRK2-G2019S dependent phenotypes and genetic back-
ground-specific changes, isogenic control lines were used [14]. The
identification of phenotypes in LRRK2-G2019S PD patient-specific
NESCs allows to gain new insights into NSC deregulations in PD
(caption on next page)
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pathogenesis and development. Finally, analysing the patient genetic
background enables to discover susceptibility factors that may control
disease-related cellular phenotypes and predispose to PD. These novel
genetic modifiers could potentially be used as biomarkers for early
diagnosis or as personalized therapeutic targets for precision medicine.
2. Results
2.1. Patient cell lines show impaired stem cell self-renewal and serine
metabolism
To get an unbiased overview of the pathways that are affected in
patients compared to healthy individuals, we assessed the tran-
scriptome of the healthy (H) vs. patients (P) NESCs lines depicted in
Fig. 1A. Quality controls regarding characterisation, derivation, gene-
editing and individual absolute values of hNESCs phenotypes can be
found in the supplements. Microarray analysis was performed and 865
significantly differentially expressed genes (DEGs) were identified be-
tween the six healthy and the six patient derived cell lines (H-6 vs. P-5),
FDR ≤0.05 [15]. Metacore pathway enrichment analysis revealed that
the transcriptional regulation of amino acid metabolism, the cell cycle,
cellular development as well as oxidative stress are within the top five
networks enriched in the PD patients compared to healthy individuals
(Fig. 1B). We decided to focus the further analysis on the deregulated
cell cycle and amino acid metabolism by assessing the corresponding
phenotypes, such as metabolic activity, proliferation and cell death
(Fig. 1C–F). MTT assay derived growth curves revealed reduced cell
viability or metabolic activity of the patient cell lines when compared
to the healthy lines (H1-6 vs. P1-5) (Fig. 1C). To link this decrease to
lower proliferation rates and increased cell death, we stained for the
mitosis marker phospho-histone H3 (PH3) (H1-6 vs. P1-5) and pro-
liferation marker Ki67 (H1, H2, H6 vs P1, P2, P1.1). In the patient-
derived lines, less cells were undergoing cell division as compared to
healthy controls (Fig. 1D and S3E). Moreover, immunostainings for
cleaved caspase 3 (CC3) (H1-6 vs. P1-5) and for pyknotic nuclei (PYK)
(H1-6 vs. P1-5), as well as flow cytometric counts for propidium iodide
(H1-2&4–5 vs. P1-5) revealed increased cell death and apoptosis in
patient-derived lines (Fig. 1E and F and S3E).
Next, we used a metabolomics approach to investigate the in-
tracellular levels of amino acids in the NESC cultures from healthy in-
dividuals and patients (H1-6 vs. P1-5) (Fig. 1G). From all amino acids
measured (H1-6 vs. P1-5), the L-serine increase in patients was the most
promising candidate (Fig. 1H). Interestingly, the most decreased amino
acid was phospho-serine, the precursor metabolite of serine (Fig. 1G),
suggesting that serine metabolism is deregulated in LRRK2-G2019S
patients. This hypothesis is further strengthened by the investigation of
serine levels in the blood plasma of 25 healthy individuals, 25 iPD
patients and 5 PD patients with the LRRK2-G2019S mutation (Fig. 1I).
(Fig. 1I), suggesting that impaired serine metabolism is caused by
LRRK2-G2019S. Furthermore, this observation supports the concept
that findings from a PD patient-specific NSC model can be replicated in
patients biofluids.
2.2. Stratification of LRRK2-G2019S dependent and independent
phenotypes
Next, we investigated whether the phenotypes we observed in pa-
tient cells (Fig. 1), were indeed caused by the LRRK2-G2019S mutation
(Fig. 2). For this purpose, we made use of the NESCs where the muta-
tion had been introduced into the healthy background (H1, H3, H6.1 vs
H1G2019S, H3G2019S, H6.1G2019S). We were able to detect pheno-
types similar to the ones observed in patient lines, indicating that the
LRRK2-G2019S mutation is sufficient to alter proliferation, cell death
and metabolic activity (Fig. 2A and B). Moreover, LRRK2-G2019S de-
pendency of these phenotypes was highlighted by treatment with the
LRRK2 inhibitor, CZC-25146, that was able to rescue the mutation-
depended increase in cell death and the decrease in mitosis (Fig. S4A).
We further analysed the serine levels upon the insertion of the mutation
and could show that LRRK2-G2019S increases serine levels in hNESCs
(Fig. 2C). Furthermore, we also detected an increase in the serine levels
in mice expressing human LRRK2-G2019S (Fig. 2D). These observa-
tions, support the hypothesis that the observed serine deregulations are
specific for the LRRK2-G2019S mutation.
Next, we gene-corrected the LRRK2-G2019S mutation in the patient
cell lines (P1, P1.1, P2 vs P1GC, P1.1 GC, P2GC). Indeed, correcting the
mutation resulted in the rescue of previously published phenotypes
[16], such as increased protein levels of alpha-Synuclein and TAU (Fig.
S3A). Strikingly, the correction of the mutation was, not able to rescue
proliferation and survival phenotypes in patient-specific NESCs
(Fig. 2E–G). Moreover, concerning the serine levels only a partial rescue
can be observed (Fig. 2H). This observation suggests that in the patient-
derived lines, the genetic background is contributing to the phenotypes.
To get further insights into the origin of the observed phenotypes and to
delineate their dependency on LRRK2-G2019S, we repeated the pro-
liferation and cell death assays in the presence of the LRRK2 kinase
inhibitor CZC-25146 [17]. Previously, CZC-25146 was shown to rescue
LRRK2-G2019S induced apoptosis in DNs [17]. Within the PD patient-
derived NESCs, increased cell death and decreased mitosis were not
rescued by inhibiting LRRK2-kinase activity (Fig. 2I and J). This ob-
servation suggests that other factors, which are independent of LRRK2-
G2019S, strongly contribute to these phenotype. Moreover, inhibiting
LRRK2 in the gene-corrected cells had as expected no effect (Fig. S4B).
These results emphazise the finding that the gene-correction of LRRK2-
G2019S was not sufficient to rescue the phenotypes and highlight the
important contribution of the genetic background.
2.3. Identification of potential susceptibility factors in the patient's genetic
background
Based on the observation that cellular phenotypes partially depend
on the information carried by the patient's genetic background, we
aimed at identifing responsible genes. For this purpose, we reanalysed
the gene expression via whole transcriptome microarray profiling
taking into account also the isogenic controls. Moreover to narrow
down, which genes could act as possible genetic modifiers, we per-
formed a stricter analysis using the eBayes method [18]. The data
Fig. 1. Patient cell lines show impaired stem cell renewal and serine metabolism compared to healthy hNESCs. (A) Summary of cell lines: patients (P) healthy donors
(H), insertion of LRRK2-G2019S (HG2019S) or gene correction (PGC). (B) Metacore pathway enrichement analysis for H1-6 vs. P1-5, based on 865 DEGs
(RankProduct). (C) Growth curve of hNESCs by MTT at day 1, 3 and 6. Data as Mean ± SEM. *p ≤ 0.05, 2-way ANOVA. Sidak's multiple comparison *p < 0.05 at
day 6. N = 6 (H1-6 vs. P1-5), n = 5. (D) Representative images of phenotypes. P hNESCs show decreased mitosis (pH3) and proliferation (Ki67). Quantifications as
Mean ± SEM. *p ≤ 0.05, t-test, GRUBB's test α=0.1, no outlier, N=6 (H1-6 vs. P1-5), n=3. For Ki67 N=3 (H1-2, H6 vs. P1-2), n=3. See Fig. S3F for
individual values. (E) Propidium Iodide positive cell count after flow cytometry. Mean ± SEM. *p≤ 0.05, t-test, GRUBB's test α=0.1, 1 outlier, N=5/6 (H1-2, H4-
6 vs. P1-5) n= 3. (F) Representative images of phenotypes. P hNESCs show increased pyknosis (white stars) and apoptosis (CC3). Average percentages of positive
cells ± SEM. *p ≤ 0.05, t-test, GRUBB's test α=0.1, no outlier for CC3, 1 outlier in H and P for PYK. N=6 (H1-6 vs. P1-5), n= 3. See Fig. S3F for individual
values. (G) Intracellular amino acid metabolite levels of hNESCs show increased serine levels in P. Data is shown as logFC, Mean ± SEM. (H) Serine metabolite levels
in P vs. H individuals. Data is shown as Mean ± SEM p≤0.053, t-test. GRUBB's test within 3 technical and 3 biological replicates per line α=0.1. 1 outlier in H2,
H3, H5 and P5. N=6 (H1-6 vs. P1-5), n=3. See also Fig. S3B for individual values. (I) Serine blood plasma levels are increased in P vs. H and in P vs. iPD cases.
Mean ± SEM. *p ≤ 0.05, t-test, GRUBB's test α= 0.1, no outliers. 1-way ANOVA p=0.0555.
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confirmed that deregulation of the NESC transcriptome is strongly in-
fluenced by the patient's genetic background. The heatmap shows that
patient cells cluster with their gene-corrected counterpart, suggesting a
limited contribution of LRRK2-G2019S alone to the changes in gene
expression (Fig. 3A). To investigate which genes could act as possible
succeptibility factors accounting for the patients' genetic background-
dependent part of the phenotypes, we evaluated the DEGs from the
Healthy vs. Patient comparison. The top 50 candidates are represented
(caption on next page)
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in a second heat map (Fig. 3B). These top candidates include genes such
as RAB32 and PTGR1 that have implications in LRRK2-G2019S induced
PD pathogenesis [19] or were linked to the PD genetic background in
DNs [20]. To further emphasize the top candidate genes we performed
a variable importance ranking based on the significance (Fig. 3C) In-
terestingly, among the top five genes that were unique to the Healthy
vs. Patient comparison we found 2 genes, ARL17a, ARL17b, in which
SNPs have been linked to PD before [21] (Fig. 3D). Other significant
DEGs involved in pathways potentially relevant for PD, were serine
racemase (SRR), neurotensin (NTS) and DLEU7 Antisense RNA 1
(DLEU7-AS1). The most promising candidates that may act as the here
sought-after genetic modifiers were SRR and NTS because of their in-
volvement in neuromodulation, -transmission and neurological dis-
eases, such as PD [22,23].
2.4. Patient cell lines show impaired SRR expression, deregulated serine
metabolism and the enzymatic product of SRR, D-serine, rescues patient
phenotypes
SRR is the enzyme that catalyzes the conversion between L-serine
and D-serine (Fig. 4A). Since serine metabolism was already affected by
LRRK2-G2019S in hNESCs (Figs. 1 and 2), we decided to focus on SRR
as a potential genetic modifier for LRRK2-G2019S induced PD. RT-
qPCR for SRR mRNA validated the reduced expression in patient cell
lines (H1-6 vs. P1-5) (Fig. 4B). Consistent with the reduced SRR ex-
pression, the patient lines showed increased levels of L-serine compared
to the healthy lines (H1-6 vs. P1-5) (Fig. 4A). Therefore, we hypothe-
sized that the reduced levels of SRR lead to increased levels of serine
and a deficiency in the conversion to D-serine (Fig. 4A). Based on the
described function of D-serine in NSCs [24,25], the deficiency in D-
serine production might contribute to the observed cellular phenotypes,
and consequently, the effects may be rescued through treatment with D-
serine. Indeed, treatment with 100 μM D-serine led to the complete
rescue of the proliferation and cell death phenotypes in PD patient-
derived cells without affecting healthy lines (H1-6 vs P1-5) (Fig. 4C).
Strikingly, this rescue is specific for the NSC-related phenotypes. No
rescue of the neuronal phenotypes (H1-6 vs. P1-5) was achievable
through D-serine treatment (Fig. S5). Furthermore, D-serine was res-
cuing LRRK2-G2019S dependent phenotypes in the three healthy lines
where we inserted the mutation (Fig. S4C). In addition, D-serine rescued
proliferation and partially rescued apotosis in the three patient lines
where the mutation had been corrected (Fig. S4D). These rescue effects
highlight the contribution of impaired serine metabolism within the
phenotypes and emphasizes the role of the LRRK2-G2019S mutation.
3. Discussion
This study supports the concept that PD is not a monogenetic dis-
ease, a common interpretation of its diversity follows the multiple-hit
hypothesis, which states that different incidences, or genetic
predispositions may to act in parallel or consecutively to cause PD [26].
Our data suggests that both a decrease in SRR expression caused by
the genetic background as well as an increase of serine levels caused by
LRRK2-G2019S influence serine metabolism. In patients both dereg-
ulations, the reduction of SRR caused by the genetic background and
the LRRK2-G2019S mutation, may complement each other (Fig. 4D).
Based on these results, we propose an interplay between impaired
serine metabolism, the PD genetic background and LRRK2-G2019S.
However, we are aware that some of the here presented results are
unexpected and have clear constrains, including the facts that the
sample sizes is limited and that some of the observed phenotypes are
rather subtle or have marginal statistical significance.
Initially, we thought that within patients LRRK2-G2019S alone
leads to increased serine levels as observed in NESCs. Increased serine
levels were, for instance, previously reported in the striatum of 6-OHDa
leasioned rats [27] and serine inversly correlates with PD progression,
suggesting that it might inhere a compensatory mechanism [28]. This
view, however, was challenged in our data by the discrepancy that
gene-correcting LRRK2-G2019S within the patient genetic background
did not rescue phenotypes, meaning that other succeptibility factors
contribute to phenotype manifestation. A screen for potential genes that
could act as genetic modifier and represent the driving force behind the
phenotypes identified SRR, which is directly involved in serine meta-
bolism. We showed that cell lines having the patient background have
decreased SRR expression, which is in accordance with existing tran-
scriptomic data from the substania nigra of PD patients [29]. Accord-
ingly it seems more likely that two independent pathways exist that
both affect serine metabolism and might act together under disease
conditions. Mouse studies showed for instance similar phenotypes in
SRR-KO and LRRK2-G2019S mice, suggesting that LRRK2-G2019S and
SRR might have opposing modulating capacities [8,30]. The me-
chanism on how LRRK2-G2019S deregulates serine levels, however,
remains an open question and the possibility of a direct interaction
between both proteins cannot be excluded (Fig. 4d).
In regards to our hypothesis that PD may have a developmental
component, patient NESCs show significant alterations in cell death and
proliferation, which are both indicators of functionally relevant devel-
opmental impairments and could have significant consequences for in
vivo neurogenesis. LRRK2 indeed is necessary for maintaining the bal-
ance between self-renewal and cell death in NESCs. Moroever, pathway
analysis confirmed that developmental genes, independent of LRRK2-
G2019S, are altered between healthy and patient cell lines demon-
strating that both LRRK2-G2019S and the patient genetic background
can influence organism development in the context of PD.
Lastly, the deregulated serine metabolism by LRRK2-G2019S and
decreased SRR expression levels consolidated the use of D-serine as
potential rescue strategy. Moreover, a pilot study described that D-
serine treatment alleviates behavioural and motor symptoms in PD
[31]. The fact that LRRK2 alone is not responsible for the investigated
impairments, could have implications on PD therapeutic strategies in
Fig. 2. LRRK2-G2019S is sufficient to increase cell death, and serine metabolism and to decrease proliferation and metabolic activity. However within patients,
LRRK2-G2019S is not necessary to maintain phenotypes. (A) Representative images of HG2019S hNESCs. Introduction of LRRK2-G2019S in H cell lines increases
pyknosis (Hoechst) and apoptosis (CC3) and reduces mitosis (PH3). Average percentage of positive cells ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, paired t-test,
GRUBB's test α= 0.1, no outliers. N= 3 (H1,H3,H6 vs. H1G2019S, H3G2019S, H6G2019S), n=3. (B) Growth curve of hNESCs by MTT after 1, 3 and 6 days.
Mean ± SEM. 2-way ANOVA followed by Sidak's multiple comparison *p < 0.05 at day 6. N = 2 (H1, H3 vs. H1G2019S, H3G2019S), n = 5. (C) Serine levels are
increased in HG2019S vs. H individuals. Mean ± SEM. **p ≤ 0.001, t-test, GRUBB's test α= 0.1, 1 outlier in H2, H3 and H5. N=2/6 (H1G2019S, H3G2019S vs.
H1-6), n=3. (D) Serine level in striatum of LRRK2-G201S carrying mice is increased compared to WT mice from the same strain. Mean ± SEM. *p ≤ 0.05, t-test,
GRUBB's test α= 0.1, 1 outlier in WT and G2019S. N=7/5. (E) Growth curve of hNESCs by MTT after 1, 3 and 6 days. Mean ± SEM. *p < 0.05, 2-way ANOVA
followed by Sidak's multiple comparison. N = 3 (P1-2 vs. P1-2 GC), n = 5. (F) Representative images of PGC hNESCs. Gene correction is not rescuing reduced mitosis
(PH3) and increased pyknosis (Hoechst) and apoptosis (CC3). (G) Quantification of B. Percentages as Mean ± SEM. *p ≤ 0.05, paired t-test, GRUBB's test α=0.1, 1
outlier for PYK (P). N=3 (P1-2 vs. P1-2 GC), n= 3. (H) Serine levels are not significantly decreased by gene-correcting LRRK2-G2019S in patient lines.
Mean ± SEM, *p ≤ 0.053, t-test, GRUBB's test α= 0.1, 1 outlier in P5 and P2GC. N=3 (P1-5 vs. P1-2 GC), n= 3. (I) Representative images of hNESCs stained for
Hoechst, PH3 and CC3 after treatment with 0.5 μM LRRK2 Inhibitor CZC-25146 in DMSO. (J) Quantification of D. Inhibition of LRRK2-G2019S is not rescuing
reduced mitosis or cell death in patient lines. Data as Mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, t-test, GRUBB's test α= 0.1, 1 outlier in Pdmso and
PLRRK2in for CC3 and PYK and Hdmso for PH3, N=6 (H1-6 vs. P1-5), n=3.
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LRRK2-G2019S carriers. SRR, and L/D-serine could serve as new ther-
apeutic targets for complementary treatment of early stage PD or may
be used as potential blood biomarkers for diagnosis, stratification and
preventive strategies. Finally, the results presented here might help to
explain the incomplete penetrance and the variable age of onset and
progression of LRRK2-G2019S carriers.
4. Experimental procedures
Detailed experimental procedures are described in the supplements
that can be found online. NESCs were generated from iPSCs, gene
edited and cultivated as described by Qing et al., 2017 and Reinhardt
et al., 2013. Antibodies and reagents for immunocytochemiststry can be
found in Table 1. Confocal images were preprocessed with Zeiss and
analysed using image J. MTT was performed using the manualfactures
protocol (Sigma). Flow cytometry is described in Walter et al., 2019.
RT-qPCR was done using Taqman probes (Table 1). Metabolite blood
and mouse extractions are described in Jäger et al., 2016 and cellular
metabolites have been analysed by the University of Leiden. Mice were
purchased from Jackson Lab Stock# 012467 derived from the WT
Fig. 3. Identification of genes deregulated in LRRK2-G2019S carriers that might act as susceptibility factors within the patient genetic background to contribute to
the observed phenotypes. (A) Heatmap showing clustering of the cell lines for the top 50 DEGs between H and P using the eBayes method, FDR≤0.05. (B) Heatmap of
top 50 DEGs between H vs. P comparison, eBayes differential expression analysis, FDR≤0.05. N=6, n=3. (C) DEGs ranked by significance to identify the top
candidates. (D) Top five DEGs between H and P are background dependent, *p < 0.05 t-test, *FDR<0.05. Each dot represents one cell line. For H vs. P N= 6 (H1-6
vs. P1-5), n = 3. For PGC N = 3 (P1-2 GC), n = 3. For HG2019S N = 2 (H1G2019S, H3G2019S), n = 3.
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Fig. 4. SRR might contribute to deregulated serine metabolism, and D-serine the metabolic product of SRR rescues phenotypes in patients. (A) Validation of SRR
expression by RT-qPCR. The H lines were set to 1. Mean ± SEM. *p ≤ 0.05, t-test. N= 6 (H1-6 vs. P1-5), n=3. (B) SRR converts L-serine to D-serine and is
downregulated in the patient genetic background. (C) Representative images of hNESCs stained with Hoechst, PH3 and CC3 after treatment with 100 μM D-serine for
6 days. Quantification: D-serine rescues cell death and mitosis in patient cell lines; Mean ± SEM. *p < 0.05, t-test, GRUBB's test α=0.1, 1 outlier in Pser for PH3
and in Hser for CC3. N=6 (H1-6 vs. P1-5), n= 3. (D) SRR acts as genetic modifier for LRRK2-G2019S induced PD. Overview showing the synthesis of previous
Figures.
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funder line C5713467. Chemical reagents and treatments can be found
in Table 1. RNA was extracted using miRNA easy kit. Samples were
processed with EMBL Genomics Core Facility using Affymetrix Human
Gene 2.0 arrays. GEO accession number GSE101534.
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